The analyses conducted by Francis et al. at 8 and 9 years, respectively, of the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT) focus on the therapy of hormone receptor-positive premenopausal BC patients without BRCA mutations [19]. Here, NR4A1 is linked to breast cancer.